Genprex Inc.
GNPXGenprex Inc. in brief
Genprex Inc. is a listed company in the Biotechnology industry, based in Austin, Texas, USA. Its market value was $3 M on 30 October 2026, which makes it the 27,573rd largest listed company in the world and the 4,477th largest in the USA on this site. It employs about 13 people. Its shares trade under the symbol GNPX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Genprex Inc.
We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.
From the company's annual report filed with the US SEC: read the report
Genprex Inc. timeline
- 2013
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔Initial public offeringFinal prospectus filed with the SEC on 13 October 2017; shares registered for exchange trading on 13 October 2017.
Events of Genprex Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,350 (Jan 2022) · #4,774 (Dec 2022) · #4,850 (Jul 2023) · #4,446 (Jan 2024) · #2,440 (Mar 2026) · #4,172 (Aug 2026) · #4,394 (Oct 2026) · #4,479 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.3×
- Free cash flow yield
- -647.8%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -203.9%
- Liabilities / assets
- 21.7%
- Profit per employee
- $-1.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-16M | $-16M | — |
| Dec 2024 | — | — | $-21M | $-21M | — |
| Dec 2023 | — | — | $-31M | $-31M | — |
| Dec 2022 | — | — | $-24M | $-24M | — |
| Dec 2021 | — | — | $-21M | $-21M | — |
| Dec 2020 | — | — | $-18M | $-18M | — |
| Dec 2019 | — | — | $-11M | $-11M | — |
| Dec 2018 | — | — | $-12M | $-12M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-15M | — | — | — | — |
| Dec 2024 | $-18M | — | — | — | — |
| Dec 2023 | $-25M | — | — | — | — |
| Dec 2022 | $-18M | $0M | $-18M | — | — |
| Dec 2021 | $-14M | $0M | $-14M | $-0.42 | — |
| Dec 2020 | $-14M | $0M | $-14M | $-0.51 | — |
| Dec 2019 | $-7M | $0M | $-7M | $-0.66 | — |
| Dec 2018 | $-7M | $0M | $-7M | $-0.90 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Nov 5, 20268-KCurrent reportOther events
- Nov 4, 20268-KCurrent reportOther events
- Oct 28, 20268-KCurrent reportOther events
- Oct 21, 20268-KCurrent reportOther events
- Aug 18, 20268-KCurrent reportOther events
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 5, 20268-KCurrent reportListing notice
- Aug 3, 20268-KCurrent reportOther events
- Jul 30, 20268-KCurrent reportListing notice · Other events
- Jul 14, 20268-KCurrent reportBylaws amended · Regulation FD disclosure · Other events
- Jun 22, 20268-KCurrent reportOther events
- Jun 18, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
Official filings of Genprex Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-16 M
- Net income
- $-16 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $10 M
- Total liabilities
- $2 M
- Total equity
- $8 M
As of December-2025
Top 20 institutional investors in Genprex Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Fiduciary Trust Co | 3,552 | New | 0.43% | $0 M | Nov 13, 2026 |
| 2 | Vanguard Capital Management LLC | 1,653 | New | 0.20% | $0 M | Nov 13, 2026 |
| 3 | UBS Group AG | 443 | New | 0.05% | $0 M | Nov 10, 2026 |
| 4 | Tower Research Capital LLC (TRC) | 260 | New | 0.03% | $0 M | Nov 16, 2026 |
| 5 | Robinhood Markets, Inc. | 61 | — | 0.01% | $0 M | Nov 18, 2026 |
| 6 | Jones Financial Companies Lllp | 56 | New | 0.01% | $0 M | Nov 13, 2026 |
| 7 | Royal Bank Of Canada | 53 | New | 0.01% | $0 M | Nov 16, 2026 |
| 8 | Cheviot Value Management, LLC | 46 | -954 (-95.40%) | 0.01% | $0 M | Nov 9, 2026 |
| 9 | BlackRock, Inc. | 10 | New | 0.00% | $0 M | Nov 13, 2026 |
| 10 | Osaic Holdings, Inc. | 8 | New | 0.00% | $0 M | Nov 12, 2026 |
| 11 | SBI Securities Co., Ltd. | 8 | New | 0.00% | $0 M | Oct 22, 2026 |
| 12 | Allworth Financial LP | 3 | New | 0.00% | $0 M | Nov 17, 2026 |
| 13 | Jpmorgan Chase & Co | 2 | New | 0.00% | $0 M | Nov 12, 2026 |
| 14 | Morgan Stanley | 2 | New | 0.00% | $0 M | Nov 13, 2026 |
| 15 | Harbour Investments, Inc. | 1 | -107 (-99.07%) | 0.00% | $0 M | Nov 9, 2026 |
| 16 | Group One Trading LLC | 1 | New | 0.00% | $0 M | Nov 10, 2026 |
| 17 | Capital Advisors, Ltd. LLC | 1 | New | 0.00% | $0 M | Oct 27, 2026 |
| 18 | Bogart Wealth, LLC | 1 | New | 0.00% | $0 M | Nov 10, 2026 |
| 19 | Global Retirement Partners, LLC | 1 | New | 0.00% | $0 M | Nov 10, 2026 |
| 20 | HighMark Wealth Management LLC | 1 | New | 0.00% | $0 M | Nov 17, 2026 |
Mutual funds holding Genprex Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 25,119 | $0 M | — | <0.01% | +79% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 5,950 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,522 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 685 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Genprex Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Brent M. LongneckerDirector | Sell | -8 | $1.230 | $10 | 9,157 | Form 4 |
| filed | Brent M. LongneckerDirector | Sellindirect | -10 | $1.230 | $12 | 0 | Form 4 |
| filed | Ryan M. ConferPresident, CEO and CFO, Director | Shares withheld for tax | -9,330 | $2.000 | $19 K | 36,331 | Form 4 |
| filed | Mark Stanley BergerChief Medical Officer | Shares withheld for tax | -7,168 | $2.000 | $14 K | 21,692 | Form 4 |
| filed | William R. Wilson Jr.Director | Grant or award | +9,000 | — | — | 9,157 | Form 4 |
| filed | Mark Stanley BergerChief Medical Officer | Grant or award | +28,500 | — | — | 28,860 | Form 4 |
| filed | Ryan M. ConferPresident, CEO and CFO, Director | Grant or award | +45,000 | — | — | 45,661 | Form 4 |
| filed | Brent M. LongneckerDirector | Grant or award | +9,000 | — | — | 9,165 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Genprex Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 6.684-for-1 split
Trading halts
- 2026-07-15 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-10-28 15:20 UTC, code LUDP, resumed 15:25 UTC
- 2025-10-20 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 464 shares at $2.04
- : 1,390 shares at $1.95
- : 808 shares at $1.81
- : 4,398 shares at $1.81
- : 148 shares at $1.98
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Genprex Inc. scorecard#
Passes 3 of the 9 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.3×Price to book 0.3× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✓Net income higher than five years earlier-$16 M-$16 M in fiscal 2025 against -$18 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$16 MNet income -$16 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-338.8%-338.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities3.9×Current ratio 3.85 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Genprex Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | 0—— | 0—— | 0—— | 0—— | 0—— | — | 0—— | 0—— | 0—— | |
| Research and development | 9.4−10.5%— | 11−40.2%— | 18+53.1%— | 12+28.3%— | 9.0r8.6+22.8%— | 7.3+271%— | 2.0+102%— | 1.0+235%— | 0.3−18.3%— | 0.4—— | |
| General and administrative | 6.1−42.7%— | 11−20.8%— | 13r13+9.2%— | 12+5.3%— | 12r11+9.8%— | 11+22.2%— | 8.7−23.6%— | 11+277%— | 3.0−20.1%— | 3.8—— | |
| Total costs and expenses | 16−26.7%— | 21−31.8%— | 31r31+30.3%— | 24+15.3%— | 21r20+15.1%— | 18+68.1%— | 11−13.6%— | 12+273%— | 3.3−19.8%— | 4.1—— | |
| Operating income | −16—— | −21—— | −31r−31—— | −24—— | −21r−20—— | −18—— | −11—— | −12—— | −3.3—— | −4.1—— | |
| Interest and finance income | — | 0.1−70.4%— | 0.2+139%— | 0.1+1655%— | 0.0−72.7%— | 0.0−32.6%— | 0.0−4.4%— | 0.0+36380%— | 0.0—— | 0—— | |
| Interest expense and finance costs | — | — | — | — | — | — | — | 0.0+1910%— | 0.0—— | 0—— | |
| Other non-operating income (expense) | — | — | — | — | — | — | — | −0.0—— | −0.0—— | 0—— | |
| Income tax | 0−100%— | 0.0—— | 0—— | 0—— | — | — | — | — | — | — | |
| Net income including minority interests | — | — | — | — | — | — | — | −12—— | −3.3—— | — | |
| Net income attributable to shareholders | −16—— | −21—— | −31—— | −24—— | −21r−20—— | −18—— | −11—— | −12—— | −3.3—— | −4.1—— | |
| Earnings per share, basic | -17.40—— | -266.89r-5.34—— | -22.56—— | -19.80r-0.50—— | -0.44r-0.42—— | -0.51—— | -0.66—— | -0.90—— | -0.29—— | -0.38—— | |
| Earnings per share, diluted | — | — | — | — | -0.42—— | -0.51—— | -0.66—— | -0.90—— | -0.29—— | -0.38—— | |
| Shares, weighted average (basic) | 0.9+1064%— | 0.1r4.0−94.1%— | 1.4+14.1%— | 1.2r48−97.5%— | 47—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | — | — | — | — | 47+32.6%— | 36+122%— | 16+16.4%— | 14+19.7%— | 12+6.1%— | 11—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.8+389%77.1% | 1.6−76.2%38.8% | 6.7−67.8%63.1% | 21−45.8%83.5% | 39+41.4%90.1% | 27+1264%87.1% | 2.0−76.7%56.7% | 8.6+5234%92.8% | 0.2−89.9%12.8% | 1.6—83.9% | |
| Receivables | — | — | 0−100%0.0% | 0.0—0.1% | 0−100%0.0% | 0.0−80.6%0.0% | 0.0−93.0%0.0% | 0.0+5.1%0.1% | 0.0+8.1%0.7% | 0.0—0.4% | |
| Other current assets | 0.5r0.5+10.5%5.2% | 0.5−40.1%11.5% | 0.8+64.0%7.4% | 0.5−5.3%1.9% | 0.5+33.0%1.2% | 0.4+124%1.2% | 0.2−27.5%4.9% | 0.2+909%2.6% | 0.0−17.2%1.9% | 0.0r0.0—1.5% | |
| Current assets | 8.4r8.4+302%82.3% | 2.1−72.4%50.4% | 7.5−64.9%70.6% | 21−45.1%85.6% | 39+41.3%91.3% | 28r31+831%88.3% | 3.0−66.4%84.2% | 8.8+4470%95.4% | 0.2−88.2%15.4% | 1.6—85.8% | |
| Property, plant and equipment | 0—0.0% | 0−100%0.0% | 0.0−65.9%0.1% | 0.0−52.6%0.1% | 0.0+23.2%0.1% | 0.0−11.7%0.1% | 0.0+83.4%1.3% | 0.0+212%0.3% | 0.0+51.3%0.6% | 0.0—0.3% | |
| Other intangible assets | — | 0−100%0.0% | 0.8+10.2%7.2% | 0.7+9.3%2.8% | 0.6+6.8%1.5% | 0.6+22.5%1.9% | 0.5+29.5%13.9% | 0.4+27.1%4.1% | 0.3+23.9%23.7% | 0.2—12.6% | |
| Non-current assets | — | — | — | — | — | — | — | — | — | 0.3—14.0% | |
| Total assets | 10r10+146%100% | 4.1−61.3%100% | 11−57.5%100% | 25−41.5%100% | 43+36.6%100% | 31+788%100% | 3.5−61.9%100% | 9.3+636%100% | 1.3−34.1%100% | 1.9—100% | |
| Accounts payable | 0.7−30.8%7.3% | 1.1−23.1%26.0% | 1.4+216%13.1% | 0.4−54.5%1.8% | 1.0+404%2.3% | 0.2−55.8%0.6% | 0.4+47.8%12.3% | 0.3−53.1%3.2% | 0.6+120%49.9% | 0.3—15.0% | |
| Current liabilities | 2.2r2.2−13.2%21.4% | 2.5−23.0%60.7% | 3.3+15.8%30.5% | 2.8+77.3%11.2% | 1.6+252%3.7% | 0.5−11.7%1.4% | 0.5+31.7%14.4% | 0.4−53.3%4.2% | 0.8+191%66.0% | 0.3—15.0% | |
| Total liabilities | 2.2r2.2−12.3%21.6% | 2.5—60.7% | — | — | 1.6—3.7% | — | — | — | — | — | |
| Retained earnings | −171—−1684% | −155—−3753% | −134—−1253% | −103—−410% | −79r−78—−185% | −58r−58—−186% | −40—−1145% | −30—−322% | −17—−1386% | −14—−740% | |
| Shareholders' equity | 8.0+391%78.4% | 1.6−78.2%39.3% | 7.4−66.7%69.5% | 22−46.0%88.8% | 41+33.5%96.3% | 31+923%98.6% | 3.0−66.0%85.6% | 8.9+1972%95.8% | 0.4−73.6%34.0% | 1.6—85.0% | |
| Total liabilities and equity | 10r10+146%100% | 4.1−61.3%100% | 11−57.5%100% | 25−41.5%100% | 43+36.6%100% | 31+788%100% | 3.5−61.9%100% | 9.3+636%100% | 1.3−34.1%100% | 1.9—100% | |
| Shares outstanding | 0.1r3.3−31.0%— | 0.2r11−85.4%— | 1.5+23.5%— | 1.2r48−97.5%— | 48+11.0%— | 43+124%— | 19+26.4%— | 15+30.0%— | 12+3.1%— | 11r0.3—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 0.3−90.9%— | 3.3−38.9%— | 5.4+14.3%— | 4.7−11.5%— | 5.3r4.3+25.9%— | 4.2+20.3%— | 3.5−35.1%— | 5.4+311%— | 1.3−50.2%— | 2.7—— | |
| Cash from operating activities | −15—— | −18r−17—— | −25—— | −18r−18—— | −14—— | −14—— | −6.9—— | −6.8—— | −2.2—— | −1.2—— | |
| Capital expenditure | — | — | — | 0—— | −0.0r−0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | |
| Intangible assets bought | — | 0—— | −0.1—— | −0.1—— | −0.0r−0.0—— | −0.1—— | −0.1—— | −0.1—— | −0.1—— | −0.1—— | |
| Cash from investing activities | 0−100%— | 0.8r0.0—— | −0.1—— | −0.1r0.1—— | −0.1—— | −2.3—— | −0.9—— | −0.1—— | −0.1—— | −0.1—— | |
| Shares issued | 22+79.3%— | 12+13.4%— | 11+164752%— | 0.0−100.0%— | 26−38.3%— | 42+3182%— | 1.3−91.8%— | 15+1838%— | 0.8−70.7%— | 2.7—— | |
| Cash from financing activities | 22+79.3%— | 12+13.4%— | 11+164752%— | 0.0−100.0%— | 26−38.3%— | 42+3182%— | 1.3−91.8%— | 15+1838%— | 0.8−70.7%— | 2.7—— | |
| Change in cash | 6.2—— | −5.1—— | −14—— | −18−256%— | 11−55.3%— | 25—— | −6.6−178%— | 8.4—— | −1.4−205%— | 1.4—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 10+3.0%— | 2.7+25.1%— | 2.7+7.4%— | 2.7+8.1%— | 2.2*−22.6%— | 2.2−20.4%— | 2.5+50.0%— | 2.5−22.4%— | 2.8r2.8*−23.6%— | 2.8—— | 1.7—— | 3.3—— | 3.7*—— | |
| General and administrative | 6.4+2.2%— | 1.5+32.5%— | 1.8−17.5%— | 1.7+22.3%— | 1.3*−11.7%— | 1.2−26.4%— | 2.2−55.0%— | 1.4−47.4%— | 1.5*−33.5%— | 1.6—— | 4.8—— | 2.7—— | 2.3r2.3*—— | |
| Total costs and expenses | 17+2.7%— | 4.3+27.6%— | 4.5−4.2%— | 4.5+13.2%— | 3.5*−18.8%— | 3.3−22.6%— | 4.7−28.2%— | 4.0−33.8%— | 4.3r4.3*−27.4%— | 4.3—— | 6.5—— | 6.0—— | 6.0r6.0*—— | |
| Operating income | −17—— | −4.3—— | −4.5—— | −4.5—— | −3.5*—— | −3.3—— | −4.7—— | −4.0—— | −4.3r−4.3*—— | −4.3—— | −6.5—— | −6.0—— | −6.0r−6.0*—— | |
| Interest and finance income | — | — | — | — | — | 0.0−70.2%— | 0.0−70.2%— | 0.0−82.8%— | 0.0*−88.1%— | 0.0—— | 0.0—— | 0.0—— | 0.0*—— | |
| Other non-operating income (expense) | — | — | — | — | — | −0.5—— | — | — | — | 0—— | — | — | — | |
| Net income attributable to shareholders | −17—— | −4.2—— | −4.4—— | −4.5—— | −3.8*—— | −3.8—— | −4.7—— | −4.0r−4.0—— | −4.3r−4.3*—— | −4.3—— | −6.5r−6.5—— | −6.0—— | −5.9*—— | |
| Earnings per share, basic | — | -5.30—— | -9.40—— | -0.64—— | — | -109.39r-5.00—— | -185.30r-0.17—— | -12.98r-0.26—— | — | -61.65r-1.23—— | -3.00—— | -3.86r-3.69—— | — | |
| Shares, weighted average (basic) | 0.8+2202%— | 0.8+2202%— | 0.5+1775%— | 7.0+2177%— | — | 0.0r0.8−50.4%— | 0.0r28−98.8%— | 0.3r15−81.1%— | — | 0.1r3.5—— | 2.2—— | 1.6—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 15—87.6% | 15+1291%87.6% | 15+1025%88.4% | 18+420%88.9% | 7.8+389%77.1% | 1.1−25.9%31.0% | 1.3−45.2%35.2% | 3.5−57.8%57.7% | 1.6−76.2%38.8% | 1.5—38.1% | 2.5—37.2% | 8.2—65.4% | 6.7—63.1% | |
| Receivables | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Other current assets | 0.8—4.8% | 0.8+37.0%4.8% | 0.7−2.9%4.0% | 0.8+8.4%3.7% | 0.5r0.5+10.5%5.2% | 0.6+42.5%17.2% | 0.7−63.4%18.5% | 0.7−31.2%11.6% | 0.5−40.1%11.5% | 0.4—11.0% | 1.9—29.3% | 1.0—8.0% | 0.8—7.4% | |
| Current assets | 16—92.4% | 16+844%92.4% | 16+670%92.4% | 19+352%92.6% | 8.4r8.4+302%82.3% | 1.7−10.6%48.1% | 2.1−53.2%53.7% | 4.2−54.9%69.3% | 2.1−72.4%50.4% | 1.9—49.1% | 4.4—66.5% | 9.2—73.4% | 7.5—70.6% | |
| Property, plant and equipment | — | — | — | — | 0—0.0% | — | — | — | 0−100%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.1% | |
| Other intangible assets | — | — | — | — | — | — | — | — | 0−100%0.0% | 0—0.0% | 0—0.0% | 0.8—6.3% | 0.8—7.2% | |
| Total assets | 18—100% | 18+392%100% | 17+348%100% | 20+238%100% | 10r10+146%100% | 3.6−8.8%100% | 3.8−42.0%100% | 6.0−52.2%100% | 4.1−61.3%100% | 3.9—100% | 6.6—100% | 13—100% | 11—100% | |
| Accounts payable | 0.8—4.3% | 0.8−53.2%4.3% | 0.3−68.5%1.7% | 1.7+8.5%8.2% | 0.7−30.8%7.3% | 1.6+24.2%45.5% | 0.9−20.8%24.3% | 1.5−29.1%25.4% | 1.1−23.1%26.0% | 1.3—33.4% | 1.2—17.8% | 2.2—17.1% | 1.4—13.1% | |
| Current liabilities | 3.8—21.7% | 3.8+48.8%21.7% | 2.3−3.9%13.7% | 3.4+56.6%16.5% | 2.2r2.2−13.2%21.4% | 2.6+13.8%71.6% | 2.4+7.8%63.7% | 2.1−43.8%35.6% | 2.5−23.0%60.7% | 2.2—57.4% | 2.3—34.2% | 3.8—30.3% | 3.3—30.5% | |
| Total liabilities | 3.8—21.7% | 3.8+35.9%21.7% | 2.3—13.7% | 3.4—16.6% | 2.2r2.2−12.3%21.6% | 2.8—78.4% | — | — | 2.5—60.7% | — | — | — | — | |
| Retained earnings | −184—−1051% | −184—−1051% | −180—−1050% | −175—−864% | −171—−1684% | −167—−4694% | −163—−4270% | −159—−2642% | −155—−3753% | −150—−3851% | −146—−2213% | −140—−1112% | −134—−1253% | |
| Shareholders' equity | 14—78.3% | 14+1687%78.3% | 15+963%86.3% | 17+338%83.4% | 8.0+391%78.4% | 0.8r0.8−53.9%21.6% | 1.4r1.4−68.0%36.3% | 3.9r3.9−55.8%64.4% | 1.6−78.2%39.3% | 1.7—42.6% | 4.3r4.3—65.8% | 8.8—69.7% | 7.4—69.5% | |
| Total liabilities and equity | 18—100% | 18+392%100% | 17+348%100% | 20+238%100% | 10r10+146%100% | 3.6−8.8%100% | 3.8−42.0%100% | 6.0−52.2%100% | 4.1−61.3%100% | 3.9—100% | 6.6—100% | 13—100% | 11—100% | |
| Shares outstanding | 1.2—— | 1.2+21.4%— | 0.5−98.5%— | 9.0−62.6%— | 0.1r3.3−31.0%— | 1.0−81.7%— | 33+1197%— | 24+1156%— | 0.2r11−85.4%— | 5.5—— | 2.6—— | 1.9—— | 1.5—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 0.2−75.5%— | 0.0+100%— | 0.1−85.1%— | 0.1−35.6%— | 0.0*−96.7%— | 0.0r0.0−95.2%— | 0.5r0.5−77.9%— | 0.2−64.3%— | 0.3*−70.9%— | 0.4—— | 2.1—— | 0.5—— | 1.0r1.0*—— | |
| Cash from operating activities | −15—— | −2.9*—— | −5.1*—— | −3.1—— | −4.1*—— | −3.2r−3.2*—— | −3.9r−3.9*—— | −4.2r−4.2—— | −3.9r−3.9*—— | −2.2r−2.2*—— | −6.6r−5.8*—— | −5.3—— | −5.0r−5.0*—— | |
| Intangible assets bought | — | — | — | — | — | — | — | — | — | — | — | −0.0—— | −0.0*—— | |
| Cash from investing activities | — | — | — | — | 0*—— | 0*—— | 0*−100%— | 0—— | −0.0r−0.0*—— | 0r0*—— | 0.8r0.0*—— | −0.0—— | −0.0*—— | |
| Shares issued | 30+101%— | 3.1*+4.6%— | 2.2*+28.7%— | 13+122%— | 11r11*+172%— | 2.9r2.9*+142%— | 1.7r1.7*+8294%— | 6.0r6.0−11.3%— | 4.0*+99570150%— | 1.2*—— | 0.0*—— | 6.8—— | 0.0r0.0*—— | |
| Cash from financing activities | 30+101%— | 3.1*+6.3%— | 2.2*+28.7%— | 13+122%— | 11*+172%— | 2.9*+142%— | 1.7r1.7*+8294%— | 6.0r6.0−11.3%— | 4.0*+99570150%— | 1.2*—— | 0.0*—— | 6.8—— | 0.0r0.0*—— | |
| Change in cash | 14—— | 0.2*—— | −2.9*—— | 10+447%— | 6.7*+5834%— | −0.2r−0.2*—— | −2.1r−2.1*—— | 1.9+26.2%— | 0.1*—— | −1.0*—— | −5.8*—— | 1.5—— | −5.0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Genprex Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $729 K | $906 K | $689 K | — |
| 2024Chief executive | $542 K | $589 K | $500 K | — |
| 2023Chief executive | $1.7 M | $910 K | $940 K | — |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Genprex Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 4 · Directors and officers 1 · Material agreement 2 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 5, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Genprex Inc.#
1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $155 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Formulations & Analytical DevelopmentNatural Sciences Managers | 1 | $155 K |
Where: Mt Juliet, TN 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Genprex Inc.
How Genprex Inc. compares in Biotechnology
- Market cap$3 M · higher than 2% of 726
- Price / book0.3× · lower than 96% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Genprex Inc.🇺🇸 | $3 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 15, 2026
- Profile updated:
- Nov 19, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Genprex Inc.? Verify and update this profile — free
Show Genprex Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.